Xenetic Biosciences Reports Q2 2026 Financials and Advances DNase Platform
The company reported financial results for the quarter ended June 30, 2026, and highlighted key preclinical data presented at ASCO and a partnership to pursue clinical trials of DNase I.
View filing at SEC.gov →